Fosun Pharma’s self-developed MEK inhibitor has been approved for marketing in China. This drug can treat related rare blood tumors
May 30, 2025
Source: drugdu
86
On May 29, Fosun Pharma announced that its independently developed Class 1 new drug Ruvometinib Tablets (trade name: Fumainin®) was officially approved for marketing by the National Medical Products Administration (NMPA). As a highly selective MEK1/2 inhibitor, Fumainin was approved for two indications for the treatment of adult patients with Langerhans cell histiocytosis (LCH) and histiocytic tumors, and children and adolescents aged 2 years and above with neurofibromatosis type I (NF1) with symptomatic, inoperable plexiform neurofibromas (PN).
Fosun Pharma's Ruvometinib has been approved for marketing, filling the gap in the treatment of rare tumors such as adult LCH. It works by blocking key signaling pathways, with impressive clinical efficacy and safety, and subsequent research and development of multiple indications is worth looking forward to.
https://www.nbd.com.cn/articles/2025-05-29/3893732.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Is Drug Working? Still Needed? July 14, 2025
- FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC July 14, 2025
- KYS2301 gel approved for clinical use in atopic dermatitis July 14, 2025
- Innovent Biologics’ Enzeshu was approved for marketing, becoming China’s first targeted drug for all patients with platinum-resistant ovarian cancer July 14, 2025
- CStone Pharmaceuticals and Istituto Gentili Enter into European Commercialization Collaboration July 14, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
